TEST:

Oncotype DX Breast Recurrence Score®Test

In the post-TAILORx era, younger age was associated with substantially more ODX testing. The association of testing with chemotherapy varied substantially by age. The impact of age on ODX testing and use of chemotherapy is substantial and warrants further study.

Interventions to prevent or treat CRCI are needed to improve the long-term quality of life of these patients treated with chemotherapy. ClinicalTrials.gov Identifier: NCT01272037.

The results warrant further investigation on a larger cohort. This framework can be a useful surrogate for participants for whom ODX testing is neither affordable nor available.

Based on our analysis, chemo use was noted in 40.8% of young, lymph node + BC patients with an RS score of 0-25. This group of patients had a relative overall survival advantage of around 40% with chemo use, further supporting the findings of the RxPONDER trial. This benefit is of particular significance in patients with a RS of 12-25. The survival advantage was present in all patients less than 50 years, regardless of the age subgroups.

Despite these advancements, challenges persist in data heterogeneity and mechanistic interpretation of radiomic biomarkers. Emerging strategies integrating radiogenomic analyses and organoid validation platforms are establishing new paradigms for precision imaging-guided therapy.

P2, N=71, Completed, Asan Medical Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Aug 2026 --> Oct 2025

In both pre- and postmenopausal women, there is no difference in 10-year OS or LR between anastrozole and tamoxifen for BC patients with low Oncotype RS. We conclude that Stage 1-3, T1-T3 pre- and postmenopausal BC patients with Oncotype RS between 0 and 17 can safely choose either medication. This finding is of particular importance for premenopausal women who wish to avoid the adverse side effects of medically induced menopause and bone deterioration associated with the anastrozole and ovarian suppression approach.

The 21-gene RS of T1-3N1M0 breast cancer is related to tumor size, grade, ER, PR, and Ki-67 index. RS is an important factor affecting DM and DFS.

The prognostic value of RS in MBC appears evident; however, sex-specific thresholds may be necessary to optimize treatment stratification. Given current data limitations, male-inclusive clinical trials are needed to elucidate the predictive value of RS in men and improve personalized treatment strategies.

P3, N=1520, Not yet recruiting, West German Study Group

This observational study highlights that the Oncotype DX test supports therapeutic de-escalation in patients with RS ≤ 25 and serves as a prognostic marker. Oncogeriatric evaluations are essential to guide adjuvant treatments in older breast cancer patients prior to using genomic signatures.

Patients receiving chemotherapy had 21 (+91.3%) more hospital accesses, 115 (+101.8%) more health services and a reimbursement of €2811 (+31.5%) higher than patients not receiving chemotherapy (median values). Oncotype DX results in lower rates of chemotherapy prescription and in possible healthcare cost savings.